344 related articles for article (PubMed ID: 32823992)
1. Parthenolide as Cooperating Agent for Anti-Cancer Treatment of Various Malignancies.
Sztiller-Sikorska M; Czyz M
Pharmaceuticals (Basel); 2020 Aug; 13(8):. PubMed ID: 32823992
[TBL] [Abstract][Full Text] [Related]
2. Combined Parthenolide and Balsalazide Have Enhanced Antitumor Efficacy Through Blockade of NF-κB Activation.
Kim SL; Kim SH; Park YR; Liu YC; Kim EM; Jeong HJ; Kim YN; Seo SY; Kim IH; Lee SO; Lee ST; Kim SW
Mol Cancer Res; 2017 Feb; 15(2):141-151. PubMed ID: 28108625
[TBL] [Abstract][Full Text] [Related]
3. Parthenolide reverses doxorubicin resistance in human lung carcinoma A549 cells by attenuating NF-κB activation and HSP70 up-regulation.
Xin Y; Yin F; Qi S; Shen L; Xu Y; Luo L; Lan L; Yin Z
Toxicol Lett; 2013 Aug; 221(2):73-82. PubMed ID: 23792430
[TBL] [Abstract][Full Text] [Related]
4. Suppressed NF-kappaB and sustained JNK activation contribute to the sensitization effect of parthenolide to TNF-alpha-induced apoptosis in human cancer cells.
Zhang S; Lin ZN; Yang CF; Shi X; Ong CN; Shen HM
Carcinogenesis; 2004 Nov; 25(11):2191-9. PubMed ID: 15256485
[TBL] [Abstract][Full Text] [Related]
5. Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-kappaB.
Oka D; Nishimura K; Shiba M; Nakai Y; Arai Y; Nakayama M; Takayama H; Inoue H; Okuyama A; Nonomura N
Int J Cancer; 2007 Jun; 120(12):2576-81. PubMed ID: 17290398
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis of parthenolide-dependent proapoptotic activity in cancer cells.
Pajak B; Gajkowska B; Orzechowski A
Folia Histochem Cytobiol; 2008; 46(2):129-35. PubMed ID: 18519227
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide.
Patel NM; Nozaki S; Shortle NH; Bhat-Nakshatri P; Newton TR; Rice S; Gelfanov V; Boswell SH; Goulet RJ; Sledge GW; Nakshatri H
Oncogene; 2000 Aug; 19(36):4159-69. PubMed ID: 10962577
[TBL] [Abstract][Full Text] [Related]
8. Parthenolide, a natural inhibitor of Nuclear Factor-kappaB, inhibits lung colonization of murine osteosarcoma cells.
Kishida Y; Yoshikawa H; Myoui A
Clin Cancer Res; 2007 Jan; 13(1):59-67. PubMed ID: 17200339
[TBL] [Abstract][Full Text] [Related]
9. Parthenolide sensitizes cells to X-ray-induced cell killing through inhibition of NF-kappaB and split-dose repair.
Mendonca MS; Chin-Sinex H; Gomez-Millan J; Datzman N; Hardacre M; Comerford K; Nakshatri H; Nye M; Benjamin L; Mehta S; Patino F; Sweeney C
Radiat Res; 2007 Dec; 168(6):689-97. PubMed ID: 18088190
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel efficacy is increased by parthenolide via nuclear factor-kappaB pathways in in vitro and in vivo human non-small cell lung cancer models.
Gao ZW; Zhang DL; Guo CB
Curr Cancer Drug Targets; 2010 Nov; 10(7):705-15. PubMed ID: 20578985
[TBL] [Abstract][Full Text] [Related]
11. Sesquiterpene lactone parthenolide markedly enhances sensitivity of human A549 cells to low-dose oxaliplatin via inhibition of NF-kappaB activation and induction of apoptosis.
Fang LJ; Shao XT; Wang S; Lu GH; Xu T; Zhou JY
Planta Med; 2010 Feb; 76(3):258-64. PubMed ID: 19774508
[TBL] [Abstract][Full Text] [Related]
12. Suppression of NF-kappaB activity by parthenolide induces X-ray sensitivity through inhibition of split-dose repair in TP53 null prostate cancer cells.
Watson C; Miller DA; Chin-Sinex H; Losch A; Hughes W; Sweeney C; Mendonca MS
Radiat Res; 2009 Apr; 171(4):389-96. PubMed ID: 19397439
[TBL] [Abstract][Full Text] [Related]
13. Parthenolide inhibits cancer stem-like side population of nasopharyngeal carcinoma cells via suppression of the NF-κB/COX-2 pathway.
Liao K; Xia B; Zhuang QY; Hou MJ; Zhang YJ; Luo B; Qiu Y; Gao YF; Li XJ; Chen HF; Ling WH; He CY; Huang YJ; Lin YC; Lin ZN
Theranostics; 2015; 5(3):302-21. PubMed ID: 25553117
[TBL] [Abstract][Full Text] [Related]
14. Parthenolide, an NF-κB inhibitor, suppresses tumor growth and enhances response to chemotherapy in gastric cancer.
Sohma I; Fujiwara Y; Sugita Y; Yoshioka A; Shirakawa M; Moon JH; Takiguchi S; Miyata H; Yamasaki M; Mori M; Doki Y
Cancer Genomics Proteomics; 2011; 8(1):39-47. PubMed ID: 21289336
[TBL] [Abstract][Full Text] [Related]
15. Parthenolide and Its Soluble Analogues: Multitasking Compounds with Antitumor Properties.
Carlisi D; Lauricella M; D'Anneo A; De Blasio A; Celesia A; Pratelli G; Notaro A; Calvaruso G; Giuliano M; Emanuele S
Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203723
[TBL] [Abstract][Full Text] [Related]
16. Parthenolide cooperates with NS398 to inhibit growth of human hepatocellular carcinoma cells through effects on apoptosis and G0-G1 cell cycle arrest.
Ralstin MC; Gage EA; Yip-Schneider MT; Klein PJ; Wiebke EA; Schmidt CM
Mol Cancer Res; 2006 Jun; 4(6):387-99. PubMed ID: 16778086
[TBL] [Abstract][Full Text] [Related]
17. Parthenolide, an inhibitor of the nuclear factor-kappaB pathway, ameliorates cardiovascular derangement and outcome in endotoxic shock in rodents.
Sheehan M; Wong HR; Hake PW; Malhotra V; O'Connor M; Zingarelli B
Mol Pharmacol; 2002 May; 61(5):953-63. PubMed ID: 11961112
[TBL] [Abstract][Full Text] [Related]
18. Sesquiterpene lactone parthenolide ameliorates bladder inflammation and bladder overactivity in cyclophosphamide induced rat cystitis model by inhibiting nuclear factor-kappaB phosphorylation.
Kiuchi H; Takao T; Yamamoto K; Nakayama J; Miyagawa Y; Tsujimura A; Nonomura N; Okuyama A
J Urol; 2009 May; 181(5):2339-48. PubMed ID: 19303104
[TBL] [Abstract][Full Text] [Related]
19. DMAPT inhibits NF-κB activity and increases sensitivity of prostate cancer cells to X-rays in vitro and in tumor xenografts in vivo.
Mendonca MS; Turchan WT; Alpuche ME; Watson CN; Estabrook NC; Chin-Sinex H; Shapiro JB; Imasuen-Williams IE; Rangel G; Gilley DP; Huda N; Crooks PA; Shapiro RH
Free Radic Biol Med; 2017 Nov; 112():318-326. PubMed ID: 28782644
[TBL] [Abstract][Full Text] [Related]
20. Antimyeloma effects of a sesquiterpene lactone parthenolide.
Suvannasankha A; Crean CD; Shanmugam R; Farag SS; Abonour R; Boswell HS; Nakshatri H
Clin Cancer Res; 2008 Mar; 14(6):1814-22. PubMed ID: 18347184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
